Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth

    2 days ago

    Macquarie has maintained an 'overperform' rating on the stock and said that the near-term momentum will be carried on the back of existing businesses.
    Click here to Read More
    Previous Article
    Nvidia Joins Hands With Global Asset Managers To Mobilise $500 Billion For AI Infrastructure
    Next Article
    Fractal Analytics Gets Buy Rating From Kotak Securities; AI Adoption Could Unlock 22% Upside

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment